EUCTR2021-001393-31-DE进行中（未招募）1 期
An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subjects =18 years of age at SCR.
- •2.Seronegative (Group 1): negative qualitative test for SARS-CoV-2 antibodies at SCR.
- •Seropositive (Group2) and Group 3): Previous COVID-19 disease or previously completed vaccination regimen with an authorized SARS-CoV-2 vaccine at least 90 days before planned trial vaccination, and a positive qualitative test for SARS-CoV-2 antibodies at SCR.Authorized” SARS-CoV-2 vaccine refers to authorization status at SCR, i.e.,subjects can be eligible if they previously received investigational vaccines that have since been authorized for emergency use or granted full market licensure. Receipt of a single dose of an authorized COVID-19 vaccine regimen in subjects with a previous diagnosis of COVID-19 or a mix/match series of 2 doses of any authorized COVID-19 vaccine will be considered as a completed vaccination.
- •3.General good health, without acute medical illness, physical exam findings, or laboratory abnormalities, as determined by the investigator.
- •4.Prior to performance of any trial specific procedures, the subject has read, signed and dated an informed consent form (ICF), having been advised of the risks and benefits of the trial in a language understood by the subject.
- •5.Body mass index (BMI) =18.5 and <40.
- •6.Female subjects of childbearing potential (WOCBP) and male subjects who are sexually active with a WOCBP must agree to the use of an effective method of birth control from at least 30 days prior to administration of the vaccine until 30 days after the vaccination. A woman is considered of childbearing potential unless post-menopausal (defined as =12 months without a menstrual period at SCR) or surgically sterilized (bilateral oophorectomy, bilateral tubal ligation, hysterectomy). Acceptable contraception methods are restricted to abstinence (abstinence only acceptable if refraining from heterosexual intercourse during the entire period of 30 days prior to administration of the vaccine until 30 days after the vaccination), double barrier contraceptives, vasectomy, intrauterine contraceptive devices or licensed hormonal products.
- •7.WOCBP must have a negative serum pregnancy test at SCR.
- •8.Negative human immunodeficiency virus antibody test (anti HIV), negative hepatitis B surface antigen (HBsAG) and negative antibody to hepatitis C virus (HCV).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 105
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 105
排除标准
- •1.Group 1 only: History of COVID-19 infection or previous vaccination with a licensed or candidate SARS-CoV-2 vaccine, or positive qualitative test for SARS-CoV-2 antibodies at SCR. Groups 2 and 3 only: History of COVID-19 infection and subsequent receipt of more than one licensed or candidate SARS-CoV-2 vaccine.
- •2.Positive test for SARS-CoV-2 infection at SCR.
- •3.Pregnant or breastfeeding women.
- •4.Subject has an acute or chronic medical condition that, in the opinion of the investigator, would render the trial procedures unsafe or would interfere with the evaluation of the responses.
- •5.History of or active autoimmune disease. History of Guillain-Barré syndrome or Reye’s syndrome. Persons with vitiligo or thyroid disease taking thyroid replacement are not excluded.
- •6.Known or suspected impairment of immunologic functions including, but not limited to, known immunodeficiency syndrome.
- •7.History of malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision at least 6 months prior to SCR that is considered to have achieved cure. Subjects with history of skin cancer must not be vaccinated at the previous tumor site.
- •8.Laboratory parameters (such as complete blood count, serum biochemistry including aspartate aminotransferase [AST], alanine amino transferase [ALT], alkaline phosphokinase [AP], bilirubin, or creatinine values), pulse rate, blood pressure, or electrocardiogram (ECG) outside normal range at SCR and deemed clinically relevant by the investigator.
- •9.Clinically significant mental disorder not adequately controlled by medical treatment.
- •10.Active or recent history (within 6 months before SCR) of chronic alcohol abuse, intravenous drug abuse, or nasal drug abuse.
- •11.History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •12.History of anaphylaxis or severe allergic reaction to any vaccine.
- •13.Having received any vaccinations or planned vaccinations with a live vaccine within 30 days prior to or after trial vaccination.
- •14.Having received any vaccinations or planned vaccinations with an inactivated vaccine within 14 days prior to or after trial vaccination.
- •15.Recent blood donation (including platelets, plasma and red blood cells) within 4 weeks prior to SCR, or planned blood donations any time during the trial.
- •16.Chronic systemic administration (defined as more than 14 days) of >5 mg prednisone (or equivalent)/day, or any other immune-modifying drugs during a period starting 3 months prior to administration of the vaccine and ending 4 weeks after the last vaccination. The use of topical, inhaled, ophthalmic and nasal glucocorticoids is allowed.
- •17.Post organ transplant subjects, whether or not receiving chronic immunosuppressive therapy.
- •18.Administration or planned administration of immunoglobulins and/or any blood products during a period starting 3 months prior to administration of the vaccine and ending 4 weeks after the last vaccination. Receipt of packed red blood cells given for an emergency indication in an otherwise healthy person, and not required as ongoing treatment is not exclusionary (for example packed red blood cells given in emergency during an elective surgery).
- •19.Use of any investigational or non-registered drug or vaccine other than the trial vaccine within 30 days preceding the administration of trial vaccine, or planned administration of such a drug or vaccine throughout the trial.
- •20.Clinical trial si
研究者
相似试验
进行中（未招募）
不适用
The Phase 2 Study of an Investigational Drug, ALN-TTRSC, in Patients with TTR Cardiac AmyloidosisEUCTR2013-002856-33-GBAlnylam Pharmaceuticals, Inc.15
未知
2 期
A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult SubjectsPrevention of Influenza infectionJPRN-jRCT2080223134TAKEDA PHARMACEUTICAL COMPANY LTD.55
已完成
2 期
Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of;Aztreonam 75 mg Powder and Solvent for Nebuliser;Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric;Patients with Cystic Fibrosis (CF) and New Onset Lower Respiratory;Tract Culture Positive for Pseudomonas aeruginosa (PA)Lung infection10024970Cystic FibrosisNL-OMON37937Gilead Sciences6
进行中（未招募）
不适用
Study of Aztreonam for Inhalation in Children with Cystic Fibrosis and New Infection of the Airways by Pseudomonas aeruginosa bacteriaCystic fibrosis and new onset lower respiratory tract culture positive for Pseudomonas aeruginosaMedDRA version: 17.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001255-36-Outside-EU/EEAGilead Sciences, Inc.105
进行中（未招募）
不适用
Study of Aztreonam for Inhalation in Children with Cystic Fibrosis and New Infection of the Airways by Pseudomonas aeruginosa bacteriaEUCTR2011-001255-36-ITGILEAD SCIENCES INC.80